These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29577629)

  • 1. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.
    Leal I; Rodrigues FB; Sousa DC; Romão VC; Duarte GS; Carreño E; Dick AD; Marques-Neves C; Costa J; Fonseca JE
    Acta Ophthalmol; 2018 Sep; 96(6):e665-e675. PubMed ID: 29577629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF inhibition for ophthalmic indications: current status and outlook.
    Rifkin LM; Birnbaum AD; Goldstein DA
    BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
    Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
    Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
    Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
    Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review.
    Calvo-Río V; de la Hera D; Blanco R; Beltrán-Catalán E; Loricera J; Cañal J; Ventosa J; Cifrián JM; Ortiz-Sanjuán F; Rueda-Gotor J; González-Vela MC; González-López M; González-Gay MA
    Clin Exp Rheumatol; 2014; 32(6):864-8. PubMed ID: 25288110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Leal I; Rodrigues FB; Sousa DC; Duarte GS; Romão VC; Marques-Neves C; Costa J; Fonseca JE
    Front Med (Lausanne); 2019; 6():104. PubMed ID: 31179280
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-tumor necrosis factor-α therapy in uveitis.
    Cordero-Coma M; Sobrin L
    Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA).
    Nguyen QD; Merrill PT; Clark WL; Banker AS; Fardeau C; Franco P; LeHoang P; Ohno S; Rathinam SR; Thurau S; Abraham A; Wilson L; Yang Y; Shams N;
    Ophthalmology; 2016 Nov; 123(11):2413-2423. PubMed ID: 27692526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of conventional immunosuppressive drugs versus anti-TNF-α agents in non-infectious non-anterior uveitis.
    Leclercq M; Langlois V; Girszyn N; Le Besnerais M; Benhamou Y; Levesque H; Muraine M; Gueudry J
    J Autoimmun; 2020 Sep; 113():102481. PubMed ID: 32586650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
    Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
    Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis.
    Liu W; Bai D; Kou L
    BMC Ophthalmol; 2023 May; 23(1):240. PubMed ID: 37248486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.
    Markomichelakis N; Delicha E; Masselos S; Sfikakis PP
    Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis.
    Thng ZX; Regenold J; Bromeo AJ; Akhavanrezayat A; Than NTT; Khatri A; Mohammadi SS; Tran ANT; Shin YU; Karaca I; Ghoraba HH; Or CCM; Nguyen QD
    Expert Opin Investig Drugs; 2024 Feb; 33(2):95-104. PubMed ID: 38299551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients.
    Mercier AE; Ribeiro E; Korobelnik JF; Delyfer MN; Rougier MB
    Ocul Immunol Inflamm; 2018; 26(3):477-484. PubMed ID: 27775458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
    Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
    J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal injection therapy in the treatment of noninfectious uveitis.
    Modorati G; Miserocchi E
    Dev Ophthalmol; 2012; 51():110-21. PubMed ID: 22517209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.